In recent years, policies such as the normalization of collection and the control of medical insurance fees have brought a huge impact on the pharmaceutical industry, forcing the transformation of pharmaceutical companies to accelerate, and while the structure is adjusted, the company is usually accompanied by the departure of senior executives and the cancellation of sales teams
.
According to incomplete statistics in the industry, since 2022, at least 250 senior executives in the pharmaceutical industry have announced their departures, including some executives
of multinational pharmaceutical companies such as AstraZeneca, Roche, and Pfizer in Greater China.
The demand for core talents in the pharmaceutical industry expanded, and more than 200 senior executives of pharmaceutical companies took up new positions during the year (Source: Pharmaceutical Network)
Judging from the reasons for the departure of hundreds of pharmaceutical company executives, they are mainly personal reasons or job adjustments
.
The industry believes that many executives are "leaving" for personal career development considerations, which also reflects the increasingly fierce competition in the entire pharmaceutical industry and the expansion
of core talent demand.
According to publicly available statistics, since the beginning of this year, there have been more than 200 senior executives of new pharmaceutical companies
.
And judging from the resumes of some new pharmaceutical company executives, the talent battle between pharmaceutical companies has begun
.
For example, in April 2022, Hengrui Pharmaceutical announced the appointment of 36-year-old Zhang Xiaojing as deputy general manager and chief medical officer (oncology) of Hengrui Pharmaceutical, and Wang Quanren as deputy general manager
of Hengrui Pharmaceutical.
Also in April, Zou Jianjun, who served as the chief medical officer and deputy general manager of Hengrui Pharmaceutical, joined Junshi Bio eight days after leaving his post and served as the company's executive director, deputy general manager and global R&D president, fully responsible for the company's global research and development work
.
For another example, on the evening of September 2, Tengshengbo Pharmaceutical announced that Luo Yongqing resigned as executive director, president and general manager of Greater China, as well as the chief executive officer of Tengshenghuachuang, a subsidiary of Tengshengbo Pharmaceutical, effective
on September 15.
At the same time, Liang Xu, vice president of scientific and medical affairs of the company, will take over as senior vice president and general manager
of Greater China.
Less than a week after Luo Yongqing's resignation, news
broke that he had taken office as executive director and chief executive officer.
From the resume, it can be found that most of these highly mobile executives have rich experience
in working in multinational pharmaceutical companies and local pharmaceutical companies at the same time.
The industry said that the talent of multinational pharmaceutical executives flowing into local pharmaceutical companies often returns to the "old owner" due to "water and soil dissatisfaction", while executives who have worked in multinational pharmaceutical companies and local pharmaceutical companies may be more adaptable, and they are more favored
by local pharmaceutical companies, especially innovative pharmaceutical companies.
For example, Zou Jianjun has nearly 30 years of rich experience
in the field of clinical treatment of tumors, anti-tumor drug research and development, and clinical research of new drugs.
Prior to joining Junshi Biologics, in addition to his employment at Hengrui Pharmaceutical, he also served as the head of medical affairs in China at Xinji Pharmaceutical, and at Bayer Pharma, he served as the medical consultant of the China Cancer Research and Development Department, the head of the treatment field, and the head of global medical affairs of Xofigo (New Jersey, the US headquarters).
In addition to his employment at Tengshengbo Pharmaceutical, Luo Yongqing also served as the global vice president and general manager of Gilead Science in China, and assisted Gilead Science in establishing its business in China, assisting in the clinical development, registration approval and successful listing of 8 innovative products, including Sovaldi, Harvoni, Epplusa and TAF, with indications for chronic hepatitis B, chronic hepatitis C and AIDS
.
In terms of direction, many executives choose to join innovative drug companies from traditional pharmaceutical companies or companies in transition
.
For example, Yunding Xinyao, a new entrant to Luo Yongqing, is a biopharmaceutical company focusing on the development and commercialization of innovative drugs, treating oncology, autoimmune diseases, cardiorenal diseases, infectious and infectious diseases
.
It said that after joining Genting Xinyao, it will continue to promote the development of late-stage product pipelines for commercialization, and will continue to invest in research and development platforms to create innovative drug product pipelines
.
In innovative drug companies, with the increasingly fierce competition in the hot target track, how to better promote product development, listing, commercialization and other aspects are major issues, and for traditional pharmaceutical companies in transition, the pressure on incoming executives may be greater, and even face the challenge of how to turn the
tide.
Overall, the industry believes that the next reshuffle of the entire pharmaceutical market will accelerate, and the flow of core talents will be more frequent
.
